Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
8 drugs in development
By Therapeutic Area
top 4
R&D Momentum
70/100
Pipeline Velocity
32/100
Trial Completion Rate
88/100
Pipeline Concentration
24/100
Pipeline Freshness
3/100
Strategic Signals
Activity
Last 14 days
Distinguishing Tics and Functional Tics Using Clinical Neurophysiological Techniques
Ultra-Low Field (ULF) Point Of Care (POC) MRI System for Study Brain Morphology and Pathology
Understanding Stroke Outcomes: Stroke Resilience, Infarct Burden, and Long-Term Cognition
Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Phenotype/Genotype Correlations in Movement Disorders
Electrical Impedance Myography: Natural History Studies in Neuromuscular Disorders and Healthy Volunteers
A Prospective Natural History Study of VHL Patients With CNS Hemangioblastomas
Surgery as a Treatment for Medically Intractable Epilepsy
Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 (IN-PASC)
Genetic Analysis of the Chiari I Malformation
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)